Genetic patterns of metalloproteinases and their tissular inhibitors - Clinicopathologic and prognostic significance in colorectal cancer

Romanian Journal of Morphology and Embryology

Volumn 52, Issue SUPPL. 1, 2011, Pages 231-236

  Surlin V ^a   Ioana, M ^a   Plesea I E ^b  

^a Department of Surgery ^*  (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

Genetic polymorphism; Matrix metalloproteinases; Tissular inhibitors of metalloproteinases

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

COLORECTAL TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS; REVIEW;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 79953151406     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Globocan 2008, http://www.iarc.fr, 2008.
2. Şurlin P, Rauten AM, Mateescu GO, Oprea B, Mariş M, Manolea H, The involvement of metalloproteinases and their tissular inhibitors in the processes of periodontal remodelling, Rom J Morphol Embryol, 2009, 50(2):181-184.
3. Amǎlinei C, Cǎruntu ID, Giuşcǎ SE, Bǎlan RA, Matrix metalloproteinases involvement in pathologic conditions, Rom J Morphol Embryol, 2010, 51(2):215-228.
4. PASCHOS KA, CANOVAS D, BIRD NC, Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases, Hippokratia, 2009, 13(1):23-31.
5. SUN XF, ZHANG H, Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas, Mol Cancer, 2006, 5:43.
6. NOVAC L, NICULESCU M, PLESEA IE, TUDORACHE ST, Matrix metaloproteinazele în sarcina normalǎ şi în avortul spontan recurent, InfoMedica, 2007, 3(141):31-33.
7. LAMBERT E, DASSÉ E, HAYE B, PETITFRÈRE E, TIMPs as multifacial proteins, Crit Rev Oncol Hematol, 2004, 49(3):187-198.
8. BAKER AH, EDWARDS DR, MURPHY G, Metalloproteinase inhibitors: biological actions and therapeutic opportunities, J Cell Sci, 2002, 115(Pt 19):3719-3727.
9. STETLER-STEVENSON WG, Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention, J Clin Invest, 1999, 103(9):1237-1241.
10. BREW K, DINAKARPANDIAN D, NAGASE H, Tissue inhibitors of metalloproteinases: evolution, structure and function, Biochim Biophys Acta, 2000, 1477(1-2):267-283.
11. AMOUR A, SLOCOMBE PM, WEBSTER A, BUTLER M, KNIGHT CG, SMITH BJ, STEPHENS PE, SHELLEY C, HUTTON M, KNÄUPER V, DOCHERTY AJ, MURPHY G, TNFalpha converting enzyme (TACE) is inhibited by TIMP-3, FEBS Lett, 1998, 435(1):39-44.
12. BAKER EA, BERGIN FG, LEAPER DJ, Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging, Br J Surg, 2000, 87(9):1215-1221.
13. BEHRENS P, MATHIAK M, MANGOLD E, KIRDORF S, WELLMANN A, FOGT F, ROTHE M, FLORIN A, WERNERT N, Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers, Int J Cancer, 2003, 107(2):183-188.
14. CHAN CC, MENGES M, ORZECHOWSKI HD, ORENDAIN N, PISTORIUS G, FEIFEL G, ZEITZ M, STALLMACH A, Increased matrix metalloproteinase 2 concentration and transcript expression in advanced colorectal carcinomas, Int J Colorectal Dis, 2001, 16(3):133-140.
15. Işlekel H, Oktay G, Terzi C, Canda AE, Füzün M, Küpelioǧlu A, Matrix metalloproteinase-9, -3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables, Cell Biochem Funct, 2007, 25(4):433-441.
16. KARAKIULAKIS G, PAPANIKOLAOU C, JANKOVIC SM, ALETRAS A, PAPAKONSTANTINOU E, VRETOU E, MIRTSOU-FIDANI V, Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon, Invasion Metastasis, 1997, 17(3):158-168.
17. LANGENSKIÖLD M, HOLMDAHL L, FALK P, IVARSSON ML, Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer, Int J Colorectal Dis, 2005, 20(3):245-252.
18. LIABAKK NB, TALBOT I, SMITH RA, WILKINSON K, BALKWILL F, Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer, Cancer Res, 1996, 56(1):190-196.
19. LUO HZ, ZHOU ZG, YANG L, YU YY, TIAN C, ZHOU B, ZHENG XL, XIA QJ, LI Y, WANG R, Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer, Jpn J Clin Oncol, 2005, 35(12):739-744.
20. PARSONS SL, WATSON SA, COLLINS HM, GRIFFIN NR, CLARKE PA, STEELE RJ, Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy, Br J Cancer, 1998, 78(11):1495-1502.
21. ROEB E, ARNDT M, JANSEN B, SCHUMPELICK V, MATERN S, Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas, Int J Colorectal Dis, 2004, 19(6):518-524.
22. SAITOH Y, YANAI H, HIGAKI S, NOHARA H, YOSHIDA T, OKITA K, Relationship between matrix metalloproteinase-7 and pit pattern in early stage colorectal cancer, Gastrointest Endosc, 2004, 59(3):385-392.
23. ZENG ZS, SHU WP, COHEN AM, GUILLEM JG, Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases, Clin Cancer Res, 2002, 8(1):144-148.
24. SHIOZAWA J, ITO M, NAKAYAMA T, NAKASHIMA M, KOHNO S, SEKINE I, Expression of matrix metalloproteinase-1 in human colorectal carcinoma, Mod Pathol, 2000, 13(9):925-933.
25. MURRAY GI, DUNCAN ME, O'NEIL P, MELVIN WT, FOTHERGILL JE, Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer, Nat Med, 1996, 2(4):461-462.
26. RING P, JOHANSSON K, HÖYHTYÄ M, RUBIN K, LINDMARK G, Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage, Br J Cancer, 1997, 76(6):805-811.
27. TAKEHA S, FUJIYAMA Y, BAMBA T, SORSA T, NAGURA H, OHTANI H, Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/ inflammatory aspect, Jpn J Cancer Res, 1997, 88(1):72-81.
28. MORÁN A, INIESTA P, DE JUAN C, GONZÁLEZ-QUEVEDO R, SÁNCHEZ-PERNAUTE A, DÍAZ-RUBIO E, RAMÓN Y CAJAL S, TORRES A, BALIBREA JL, BENITO M, Stromelysin-1 promoter mutations impair gelatinase B activation in high microsatellite instability sporadic colorectal tumors, Cancer Res, 2002, 62(13):3855-3860.
29. MORI M, BARNARD GF, MIMORI K, UEO H, AKIYOSHI T, SUGIMACHI K, Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas, Cancer, 1995, 75(6 Suppl):1516-1519.
30. ADACHI Y, YAMAMOTO H, ITOH F, HINODA Y, OKADA Y, IMAI K, Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers, Gut, 1999, 45(2):252-258.
31. MASAKI T, MATSUOKA H, SUGIYAMA M, ABE N, GOTO A, SAKAMOTO A, ATOMI Y, Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas, Br J Cancer, 2001, 84(10):1317-1321.
32. OGAWA M, IKEUCHI K, WATANABE M, ETOH K, KOBAYASHI T, TAKAO Y, ANAZAWA S, YAMAZAKI Y, Expression of matrix metalloproteinase 7, laminin and type IV collagenassociated liver metastasis in human colorectal cancer: immunohistochemical approach, Hepatogastroenterology, 2005, 52(63):875-880.
33. ZUZGA DS, GIBBONS AV, LI P, LUBBE WJ, CHERVONEVA I, PITARI GM, Overexpression of matrix metalloproteinase 9 in tumor epithelial cells correlates with colorectal cancer metastasis, Clin Transl Sci, 2008, 1(2):136-141.
34. LEEMAN MF, CURRAN S, MURRAY GI, New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression, J Pathol, 2003, 201(4):528-534.
35. BODEY B, BODEY B JR, SIEGEL SE, KAISER HE, Prognostic significance of matrix metalloproteinase expression in colorectal carcinomas, In Vivo, 2000, 14(5):659-666.
36. BISTER VO, SALMELA MT, KARJALAINEN-LINDSBERG ML, URIA J, LOHI J, PUOLAKKAINEN P, LOPEZ-OTIN C, SAARIALHOKERE U, Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer, Dig Dis Sci, 2004, 49(4):653-661.
37. ASANO T, TADA M, CHENG S, TAKEMOTO N, KURAMAE T, ABE M, TAKAHASHI O, MIYAMOTO M, HAMADA J, MORIUCHI T, KONDO S, Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma, J Surg Res, 2008, 146(1):32-42.
38. SVAGZDYS S, LESAUSKAITE V, PANGONYTE D, SALADZINSKAS Z, TAMELIS A, PAVALKIS D, Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma, Tohoku J Exp Med, 2011, 223(1):67-73.
39. HURST NG, STOCKEN DD, WILSON S, KEH C, WAKELAM MJ, ISMAIL T, Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients, Br J Cancer, 2007, 97(7):971-977.
40. OBERG A, HÖYTHYÄ M, TAVELIN B, STENLING R, LINDMARK G, Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer, Anticancer Res, 2000, 20(2B):1085-1091.
41. ISHIDA H, MURATA N, HAYASHI Y, TADA M, HASHIMOTO D, Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients, Surg Today, 2003, 33(12):885-892.
42. HOLTEN-ANDERSEN MN, STEPHENS RW, NIELSEN HJ, MURPHY G, CHRISTENSEN IJ, STETLER-STEVENSON W, BRÜNNER N, High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer, Clin Cancer Res, 2000, 6(11):4292-4299.
43. MROCZKO B, GROBLEWSKA M, OKULCZYK B, KEDRA B, SZMITKOWSKI M, The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients, Int J Colorectal Dis, 2010, 25(10):1177-1184.
44. MURASHIGE M, MIYAHARA M, SHIRAISHI N, SAITO T, KOHNO K, KOBAYASHI M, Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors, Jpn J Clin Oncol, 1996, 26(5):303-309.
45. Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, Fernebro E, E.O.- R.A.B. GROUP, Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study, Eur J Cancer, 2004, 40(1):64-72.
46. HOLTEN-ANDERSEN MN, FENGER C, NIELSEN HJ, RASMUSSEN SCHROHL AS, CHRISTENSEN IJ, Brünner N, KRONBORG O, Plasma TIMP-1 in patients with colorectal adenomas: a prospective study, Eur J Cancer, 2004, 40(14):2159-2164.
47. KOPITZ C, GERG M, BANDAPALLI OR, ISTER D, PENNINGTON CJ, HAUSER S, FLECHSIG C, KRELL HW, ANTOLOVIC D, BREW K, NAGASE H, STANGL M, VON WEYHERN CW, BRÜCHER BL, BRAND K, COUSSENS LM, EDWARDS DR, KRÜGER A, Tissue inhibitor of metalloproteinases- 1 promotes liver metastasis by induction of hepatocyte growth factor signaling, Cancer Res, 2007, 67(18):8615-8623.
48. HILSKA M, ROBERTS PJ, COLLAN YU, LAINE VJ, KÖSSI J, HIRSIMÄKI P, RAHKONEN O, LAATO M, Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer, Int J Cancer, 2007, 121(4):714-723.
49. WAAS ET, HENDRIKS T, LOMME RM, WOBBES T, Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients, Dis Colon Rectum, 2005, 48(4):700-710.
50. DECOCK J, PARIDAENS R, YE S, Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer, Clin Genet, 2008, 73(3):197-211.
51. SU L, ZHOU W, ASOMANING K, LIN XH, WAIN JC, LYNCH TJ, LIU G, CHRISTIANI DC, Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer, Carcinogenesis, 2006, 27(5):1024-1029.
52. FANG S, JIN X, WANG R, LI Y, GUO W, WANG N, WANG Y, WEN D, WEI L, ZHANG J, Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China, Carcinogenesis, 2005, 26(2):481-486.
53. BEYZADE S, ZHANG S, WONG YK, DAY IN, ERIKSSON P, YE S, Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction, J Am Coll Cardiol, 2003, 41(12):2130-2137.
54. JORMSJÖ S, WHATLING C, WALTER DH, ZEIHER AM, HAMSTEN A, ERIKSSON P, Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients, Arterioscler Thromb Vasc Biol, 2001, 21(11):1834-1839.
55. GHILARDI G, BIONDI ML, ERARIO M, GUAGNELLINI E, SCORZA R, Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms, Clin Chem, 2003, 49(11):1940-1942.
56. LIÈVRE A, MILET J, CARAYOL J, LE CORRE D, MILAN C, PARIENTE A, NALET B, LAFON J, FAIVRE J, BONITHON-KOPP C, OLSCHWANG S, BONAITI-PELLIÉ C, LAURENT-PUIG P; MEMBERS OF THE ANGH GROUP, Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma, BMC Cancer, 2006, 6:270.
57. ZINZINDOHOUÉ F, LECOMTE T, FERRAZ JM, HOULLIER AM, CUGNENC PH, BERGER A, BLONS H, LAURENT-PUIG P, Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer, Clin Cancer Res, 2005, 11(2 Pt 1):594-599.
58. HINODA Y, OKAYAMA N, TAKANO N, FUJIMURA K, SUEHIRO Y, HAMANAKA Y, HAZAMA S, KITAMURA Y, KAMATANI N, OKA M, Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer, Int J Cancer, 2002, 102(5):526-529.
59. XU E, LAI M, LǓ B, XING X, HUANG Q, No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese, Dis Colon Rectum, 2006, 49(9):1439-1444.
60. ELANDER N, SÖDERKVIST P, FRANSÉN K, Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer, Anticancer Res, 2006, 26(1B):791-795.
61. GHILARDI G, BIONDI ML, MANGONI J, LEVITI S, DEMONTI M, GUAGNELLINI E, SCORZA R, Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness, Clin Cancer Res, 2001, 7(8):2344-2346.
62. WOO M, PARK K, NAM J, KIM JC, Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer, J Gastroenterol Hepatol, 2007, 22(7):1064-1070.
63. XU E, LAI M, LV B, XING X, HUANG Q, XIA X, A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer, Biochem Biophys Res Commun, 2004, 324(3):999-1003.
64. XU EP, HUANG Q, LU BJ, XING XM, LAI MD, The correlation between polymorphisms of matrix metalloproteinase-2 and -9 genes and colorectal cancer of Chinese patients, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2006, 23(1):78-81.
65. XU E, XIA X, LÜ B, XING X, HUANG Q, MA Y, WANG W, LAI M, Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese, Mol Carcinogenesis, 2007, 46(11):924-929.
66. XING LL, WANG ZN, JIANG L, ZHANG Y, XU YY, LI J, LUO Y, ZHANG X, Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer, World J Gastroenterol, 2007, 13(34):4626-4629.
67. PENG B, CAO L, WANG W, XIAN L, JIANG D, ZHAO J, ZHANG Z, WANG X, YU L, Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a metaanalysis of 50 case-control studies, Mutagenesis, 2010, 25(1):41-48.
68. MCCOLGAN P, SHARMA P, Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects, Int J Cancer, 2009, 125(6):1473-1478.